Recent Finacing
Recent Raise
Integrated Nanotherapeutics develops a multi-cargo lipid nanoparticle platform delivering mRNA-encoded antigens and immune‑modifying small molecules to induce antigen-specific tolerance, with lead program targeting beta‑cell preservation in type 1 diabetes.
